Acadia Pharmaceuticals Collaborates with Saniona to Develop and Commercialize SAN711
Shots:
- Acadia & Saniona have entered into an exclusive worldwide licensing agreement to develop & commercialize SAN711 (GABAA-α3 positive allosteric modulator)
- The first disease that the alliance has planned for SAN711 is essential tremor, with its P-II trial anticipated in 2026. Acadia will oversee the development, regulatory approvals & global commercialization plus will fund Saniona's ongoing P-I study & planned P-II
- Saniona is entitled to receive $28M upfront, ~$582M milestones ($147M development & commercial milestones for first & second indications + $435M on achieving threshold annual net sales globally) as well as mid-single digits to low double digits net-sales-based tiered royalties
Ref: Acadia | Image: Acadia
Related News:- Health Canada Accepts Filling and Priority Review of Acadia’s TROFINETIDE for Rett Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
